Compare FLNC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | EVO |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.7M | 1.1B |
| IPO Year | 2021 | 2021 |
| Metric | FLNC | EVO |
|---|---|---|
| Price | $19.29 | $3.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $14.05 | $7.00 |
| AVG Volume (30 Days) | ★ 5.5M | 259.6K |
| Earning Date | 02-09-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,830,000.00 | $887,396,457.00 |
| Revenue This Year | $50.83 | N/A |
| Revenue Next Year | $20.86 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.46 | $2.84 |
| 52 Week High | $25.85 | $5.10 |
| Indicator | FLNC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 50.06 |
| Support Level | $18.91 | $3.03 |
| Resistance Level | $21.15 | $3.05 |
| Average True Range (ATR) | 2.07 | 0.09 |
| MACD | -0.43 | 0.03 |
| Stochastic Oscillator | 11.98 | 78.87 |
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.